SLFN11 and lung carcinoma: Similarly, when analyzing only lung cancer patients who received adjuvant chemotherapy (drugs not specified), there was a significant OS benefit in patients with high SLFN11 expression in one dataset (HR = 3.72, p = 0.031, Fig 3E) and a trend towards benefit in a second dataset (HR = 2.29, p = 0.057, Fig 3F).